1109 GMT - Fresenius Medical Care's update on its midterm targets looks positive, but broadly in line with elevated expectations, Barclays analysts say in a research note. Investors likely anticipated a 500 million-euro buyback, so news that the German dialysis company plans buybacks of 1 billion euros over two years is in line with expectations, the analysts say. The company is targeting an adjusted operating profit margin in the mid-teens by 2030. "Whilst we don't have reliable consensus out to 2030--consensus is at 12.0% for 2027--we believe this is likely in line with buyside expectations, which have been building into the [capital markets day]," Barclays says. Shares fall 4.1%. (adria.calatayud@wsj.com)
(END) Dow Jones Newswires
June 17, 2025 07:09 ET (11:09 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.